Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model

Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model

Malignant melanoma is an aggressive type of skin cancer whose incidence is increasing globally. Although surgery is effective in early stage melanoma, patients with advanced melanoma only have a 20% 5-year survival rate. Hence, combinations of existing and new immunotherapy technologies and immunoth...

Full description

Bibliographic Details
Main Authors: Lukasz Kuryk, Anne-Sophie W. Møller, Magnus Jaderberg
Format: Article
Language:English
Published: Taylor & Francis Group 2019-02-01
Series:OncoImmunology
Subjects:
oncos-102
pembrolizumab
melanoma
nog
immunogenic cell death
pd-1 inhibitor
antitumor
cancer vaccine
oncolytic adenovirus
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1532763

Internet

http://dx.doi.org/10.1080/2162402X.2018.1532763

Similar Items